


A
2-7
B
REGN10987
C
2-38
D
C135
E
CoV2-2130
F
2-36
G
COVA 1-16
H
1-20
I
2-15
J
2-43
K
C121
L
LY CoV 555
M
2-30
N
REGN10933
O
C86
P
1-57
Q
REGN10985
R
S309
S
CoV2-2196
T
CR3022
WA1
% Neutralization
Antibody conc. (µg/mL)

FIGS. 1A-T


A
448
B
4.8
C
5.24
D
1.69
E
1.87
F
2.51
G
2.17
H
4.18
I
4.19
J
5.7
WA1
B.1.351
B.1.351.2-7
% Neutralization
Antibody conc. (µg/mL)

FIGS. 2A-J

mAb	IC50 (ug/mL)		
	WA1	B.1.351	B.1.351.2-7
2-7	0.009	0.008	>100
REGN10987	0.002	0.007	>100
2-38	1.104	3.863	>100
C135	0.006	0.006	0.082
Cov2-2130	0.006	0.002	3.903
2-36	0.136	0.285	0.49
COVA1-16	0.487	0.429	0.533
1-20	0.015	10.002	24.259
2-15	0.001	>100	>100
2-43	0.006	>100	>100
C121	0.008	>100	>100
LY CoV555	0.004	>100	>100
2-30	0.074	>100	>100
REGN10933	0.002	10.288	12.417
CB6	0.08	>100	>100
1-57	0.006	0.031	0.049
REGN10985	0.042	0.008	0.013
S309	0.014	0.031	0.031
COv2-2196	0.003	0.019	0.007
CR3022	19.09	ND	>100

FIG. 3

mAb	IC50 (ug/mL)		
	WA1	B.1.351	B.1.351.2-7
4A8	0.013	>100	>100
4-8	0.04	>100	>100
5-24	0.005	>100	>100
1-68	0.01	>100	>100
1-87	0.031	>100	>100
2-51	0.011	ND	>100
2-17	0.022	10.004	>100
4-18	0.058	>100	>100
4-19	0.168	>100	>100
5-7	0.044	3.733	>100

FIG. 4



S1
S1/S2
S2
NTD
RBD
FP
HR1
CH
CD
USA/WA1
B.1.351
B.1.351.2-7
QTNSPRRAR

FIG. 5




FIG. 6